This post was originally published on this site Adding the immunotherapy Keytruda (pembrolizumab) to chemotherapy increases the number of women with early triple-negative breast cancer who clear all signs of cancer, and tends to prolong survival without complications or symptoms, according to the latest results from the KEYNOTE-522 trial. “The data suggest that the improved pathological…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Erleada-ADT Combo Increases Survival of mCSPC Patients Without Affecting Quality of Life, Phase 3 Trial Shows
This post was originally published on this site Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without compromising their quality of life — a Phase 3 clinical trial shows. Those findings were presented in the…
HealthWell Foundation Offers Treatment Payment Assistance for Mantle Cell Lymphoma
This post was originally published on this site To allow patients to focus on treatment and not cost, the HealthWell Foundation is offering copayment and insurance premium assistance to people with mantle cell lymphoma (MCL) who are on Medicare. The non-profit organization will provide up to $8,500 in financial aid as a yearlong grant to…
Long-term Hormone Therapy Does More Harm than Good in Prostate Cancer Patients with Low PSA Levels After Surgery, Analysis Shows
This post was originally published on this site Men who see their prostate cancer returning after surgery see no benefits from adding long-term hormone therapy to salvage radiation therapy if their PSA levels are low; instead, they might be at higher risk of dying from causes other than cancer, like cardiac or neurological problems, a…
Zejula Prolongs Life Without Disease Worsening in Newly Diagnosed Advanced Ovarian Cancer, Trial Shows
This post was originally published on this site Maintenance treatment with Zejula (niraparib) prolongs the time lived without disease worsening in women with newly diagnosed advanced ovarian cancer who are responding to their first-line platinum-based chemotherapy — regardless of mutations in DNA repair genes — a Phase 3 clinical trial has shown. Patients treated with…
Myeloma Crowd Invites Patients to Join Study Investigating Link Between Psoriasis and Myeloma
This post was originally published on this site The Myeloma Crowd is inviting multiple myeloma patients with psoriasis to join a new study to uncover possible correlations between the two disorders. Study participation is through Myeloma Crowd’s HealthTree platform, where more than 4,500 myeloma patients are currently registered. Launched last fall, the free digital tool…
Opdivo Superior to Chemotherapy in Patients with Advanced Esophageal Cancer, Trial Shows
This post was originally published on this site Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant or intolerant to combination therapy with fluoropyrimidine and platinum-based treatments, the ATTRACTION-3 clinical trial shows. Opdivo demonstrated a…
Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows
This post was originally published on this site Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation titled, “Overall survival (OS) results of the phase III…
Fujifilm SonoSite, AI2 Incubator Work on Using AI to Improve Ultrasound Imaging
This post was originally published on this site Fujifilm SonoSite is collaborating with the Allen Institute of Artificial Intelligence (AI2) Incubator to use artificial intelligence to improve the accuracy of ultrasound images, the standard way to detect ovarian cancer. A developer of bedside and point-of-care ultrasound, Fujifilm SonoSite paired with the AI2 Incubator to use…
Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show
This post was originally published on this site IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials show. The data, confirming that both trials achieved their primary endpoints, were presented at the 22nd Annual…
Phio Partners with German Research Center to Develop New Generation of Cancer Immunotherapies
This post was originally published on this site Phio Pharmaceuticals and researchers with Helmholtz Zentrum München — the German Research Center for Environmental Health (HMGU) — are working together to develop new approaches to boost the immune system in fighting cancer. The collaboration aims to use Phio’s proprietary self-delivering RNAi (sd-rxRNA) technology to inhibit checkpoint molecules in…
Liproca Depot Shows Promise for Treatment of Early-Stage Prostate Cancer
This post was originally published on this site A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy in untreated men with localized prostate cancer, according to early results of a Phase 2b clinical trial. The LPC-004 Phase 2b trial (NCT03348527) is ongoing at specialist urology clinics in Canada, Lithuania, and…